Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
UK Pharmaceuticals And Healthcare Industry
SWOT — 6
United Kingdom Political
SWOT — 7
United Kingdom Economic
SWOT — 7
Pharmaceutical Business Environment
Rating — 8
Table: Western Europe Pharmaceuticals Business
Environment Ratings For Q309 — 8
Limits of Potential
Returns — 9
Risks to Realisation of
Returns — 9
UK – Market
Summary — 11
Regulatory Regime — 13
Recent NICE Recommendations — 16
Innovative
Medicines — 17
Generic Medicines — 18
OTC Medicines — 18
Recent EU Regulatory
Developments — 20
Intellectual Property
Issues — 22
Counterfeit
Pharmaceuticals — 23
Table: Examples Of Recalls Of
Counterfeit Medicines In The UK — 24
Pricing
Regime — 25
Reimbursement Regime — 28
Industry Developments — 30
Epidemiology — 30
Healthcare
Sector — 32
Healthcare Financing — 33
Health Insurance — 35
Wholesale
Sector — 37
Retail Sector — 39
Table:
Registered Pharmacy Premises In The UK (2007) — 40
Parallel Imports — 41
Health
Tourism — 43
Research and Development
Sector — 44
Clinical Trials — 45
Biotechnology — 47
Medical
Devices — 48
Industry Forecast
Scenario — 50
Overall Market
Forecast — 50
Table: UK’s Drug Market Indicators,
2004-2013 — 51
Key Growth Factors –
Industry — 52
Table: UK’s Health Expenditure
Indicators, 2004-2013 — 53
Key Growth Factors –
Macroeconomic — 54
Table: United Kingdom –
Macroeconomic Forecasts — 55
Prescription Drug Market
Forecast — 56
Table: UK’s Prescription Drug Market
Indicators, 2004-2013 (US$mn unless otherwise
indicated) — 57
OTC Market
Forecast — 58
Table: UK’s OTC Market Indicators,
2004-2013 (US$mn unless otherwise stated) — 60
Patented
Market Forecast — 61
Table: UK’s Patented Market
Indicators Forecast, 2004-2013 — 62
Generics Market
Forecasts — 63
Table: UK’s Generics Market
Indicators, 2004-2013 — 64
Export/Import
Forecasts — 65
Table: UK’s Sectoral Trade Forecast
Indicators, 2004-2013 (US$mn) — 66
Key Risks to BMI
Forecasts — 66
Competitive
Landscape — 68
Table: Leading Pharmaceutical Corporations
in the UK by Market Share (2007) — 69
Table: Top
pharmaceutical products in the UK (2007) — 70
Table: Cost
Of Prescriptions* Dispensed In Various Disease Areas
(GBPmn) — 72
Company Profiles — 73
Leading Multinational Manufacturers — 73
Pfizer — 73
Novartis — 76
Sanofi-Aventis — 78
Merck & Co — 80
Leading Indigenous Manufacturers — 82
GlaxoSmithKline — 82
AstraZeneca — 88
Country Snapshot: UK Demographic Data — 92
Section 1:
Population — 92
Table: Demographic Indicators,
2005-2030 — 92
Table: Rural/Urban Breakdown,
2005-2030 — 93
Section 2: Education and
Healthcare — 93
Table: Education,
2002-2005 — 93
Table: Vital Statistics,
2005-2030 — 93
Section 3: Labour Market and Spending
Power — 94
Table: Employment Indicators,
2000-2005 — 94
Table: Consumer Expenditure, 2000-2011
(US$) — 94
Table: Average Annual Wages,
2000-2012 — 95
BMI Forecast
Modelling — 96
How We Generate Our Pharmaceutical Industry
Forecasts — 96
Pharmaceutical Business Environment Ratings
Methodology — 97
Ratings Overview — 97
Table: Pharmaceutical Business Environment Indicators — 98
Weighting — 99
Table: Weighting Of
Components — 99
Sources — 99
| 
View Cart
